TY - JOUR
T1 - Cholestatic liver diseases
T2 - An era of emerging therapies
AU - Samant, Hrishikesh
AU - Manatsathit, Wuttiporn
AU - Dies, David
AU - Shokouh-Amiri, Hosein
AU - Zibari, Gazi
AU - Boktor, Moheb
AU - Alexander, Jonathan Steve
N1 - Publisher Copyright:
© The Author(s) 2019.
PY - 2019/7/1
Y1 - 2019/7/1
N2 - Recently the field of cholestasis has expanded enormously reflecting an improved understanding of the molecular mechanisms underlying bile secretion and its perturbation in chronic cholestatic disease. Novel anti-cholestatic therapeutic options have been developed for patients not favorably responding to ursodeoxycholic acid (UDCA), the current standard treatment for cholestatic liver disease. Important novel treatment targets now also include nuclear receptors involved in bile acid (BA) homoeostasis like farnesoid X receptor and G proteincoupled receptors e.g., the G-protein-coupled BA receptor "transmembrane G coupled receptor 5". Fibroblast growth factor-19 and enterohepatic BA transporters also deserve attention as additional drug targets as does the potential treatment agent norUDCA. In this review, we discuss recent and future promising therapeutic agents and their potential molecular mechanisms in cholestatic liver disorders.
AB - Recently the field of cholestasis has expanded enormously reflecting an improved understanding of the molecular mechanisms underlying bile secretion and its perturbation in chronic cholestatic disease. Novel anti-cholestatic therapeutic options have been developed for patients not favorably responding to ursodeoxycholic acid (UDCA), the current standard treatment for cholestatic liver disease. Important novel treatment targets now also include nuclear receptors involved in bile acid (BA) homoeostasis like farnesoid X receptor and G proteincoupled receptors e.g., the G-protein-coupled BA receptor "transmembrane G coupled receptor 5". Fibroblast growth factor-19 and enterohepatic BA transporters also deserve attention as additional drug targets as does the potential treatment agent norUDCA. In this review, we discuss recent and future promising therapeutic agents and their potential molecular mechanisms in cholestatic liver disorders.
KW - Bile acids
KW - Cholestatic liver disease
KW - Drug therapy
KW - Nuclear receptor agonists
UR - http://www.scopus.com/inward/record.url?scp=85069463078&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85069463078&partnerID=8YFLogxK
U2 - 10.12998/wjcc.v7.i13.1571
DO - 10.12998/wjcc.v7.i13.1571
M3 - Short survey
C2 - 31367616
AN - SCOPUS:85069463078
SN - 2307-8960
VL - 7
SP - 1571
EP - 1581
JO - World Journal of Clinical Cases
JF - World Journal of Clinical Cases
IS - 13
ER -